Edit here your fullwidth slider

VIVOS INC. (OTCQB: RDGL)

Vivos Inc., a pharmaceutical company in the process of researching and developing minimally invasive treatments to combat cancer has developed an Yttrium-90 based brachytherapy injectable device, for the treatment of tumors in animals (IsoPet®) and in humans (RadioGel™). Brachytherapy uses highly localized radiation to destroy cancerous tumors by placing a radioactive isotope directly inside the treatment area using the company’s proprietary hydrogel formulation.

$1B+

Global Brachytherapy Market

125+

RadioGel™ Team | Years of Experience

17

Trademark Protected Countries

8

Licensed Patents

Our Strategy: The Company obtained clarification from the FDA Center for Veterinary Medicine that IsoPet® is classified as a device for skin cancer therapy in cats and dogs. The FDA also reviewed and approved the product labeling. FDA does not require pre-market approval for veterinary devices so no additional approval is required for treating skin cancer, which is the largest market sector. Vivos is positioning itself so that after this demonstration phase, The Company can begin to generate revenues through the sale of IsoPet® to University animal hospitals and private veterinary clinic consortiums.
Dr. Mike Korenko | President • CEO

CURRENT RELEASE

Vivos Inc. Announces Listing to the OTCQB

Richland WA, Sept. 18, 2019 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc. a company engaged in the development and commercialization of minimally invasive brachytherapy treatments to combat cancer in animals and humans, today announced that its common shares have been approved for trading on the OTCQB Marketplace (OTCQB) under the symbol “RDGL” effective as of the open of trading today.

"The listing of our common stock to the OTCQB Exchange is an important milestone for Vivos Inc," said Mike Korenko Vivos Inc CEO. “We look forward to continuing to increase the visibility of Vivos Inc. and believe that the broader exposure afforded by the OTCQB is another important step in that process. We are working diligently to increase the investment community’s awareness of Vivos Inc. as part of our larger mandate to inform the veterinary and medical community about Isopet® and Radiogel™.”

The OTCQB is a venture market operated by OTC Markets Group and designed for early-stage and developing US and international companies. To be eligible, companies must be current in their reporting and undergo an annual verification and management certification process. To learn more, visit otcmarkets.com.

About Vivos Inc. (OTCQB:RDGL) >> Read Full Release

PRESS RELEASES

Click here for more news and updates

Stock Quote

Links

VIVOS Inc. (OTCQB: RDGL)
719 Jadwin Avenue. Richland, Washington 99352 US
T: 509.736.4000 E: mkorenko@radiogel.com